Evidence map›Paper›PMID 25873569›Full record

ReviewThe lancet. Diabetes & endocrinology2015

Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.

Emily S Tonorezos, Melissa M Hudson, Angela B Edgar, Leontien C Kremer, Charles A Sklar, W Hamish B Wallace, Kevin C Oeffinger

Open access · greenAbstract readReview
In one paragraph

Review in The lancet. Diabetes & endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Endocrine late effects in survivors of infantile acute lymphoblastic leukemia.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2023
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Late endocrine effects of childhood cancer.Nature reviews. Endocrinology · 2016
    Review
  14. Obesity and Metabolic Disease After Childhood Cancer.Oncology (Williston Park, N.Y.) · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Emily S TonorezosDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Melissa M HudsonDepartments of Oncology, Epidemiology and Cancer Control, and Psychology, St Jude Children's Research Hospital, Memphis, TN, USA.
Angela B EdgarDepartment of hematology and Oncology, Royal Hospital for Sick Children, Edinburgh, Scotland.
Leontien C KremerDepartment of Paediatric Oncology, Emma Children's Hospital and Academic Medical Centre, Amsterdam, Netherlands.
Charles A SklarDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
W Hamish B WallaceDepartment of hematology and Oncology, Royal Hospital for Sick Children, Edinburgh, Scotland.
Kevin C OeffingerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: oeffingk@mskcc.org.
Memorial Sloan Kettering Cancer Center · USRoyal Hospital for Children · GBEmma Kinderziekenhuis · NLSt. Jude Children's Research Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Exercise and QUality diet After LeukemiaR01CA187397 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI TONOREZOS, EMILY SMITH · 2014 to 2018
$3.2M
Survivorship: Mentoring and Bridging Primary Care and OncologyK05CA160724 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OEFFINGER, KEVIN CHARLES · 2011 to 2015
$821k
NCI NIH HHS K05 CA160724NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA187397
6 · The paper itself

Abstract

5 year survival for childhood and adolescent cancer in developed countries is now in excess of 80% and the number of survivors of cancer continues to increase worldwide. After completion of therapy, many of these survivors will face a lifelong risk of endocrine late effects. We summarise the available evidence related to the prevalence and risk factors for endocrine late effects among adult survivors of childhood and adolescent cancer. Present screening, surveillance, and treatment recommendations differ by country and region, so we also highlight the continued effort to harmonise the international guidelines for this population.

Indexed as

AdolescentAdultAntineoplastic AgentsDisease ManagementEndocrine System DiseasesHumansNeoplasmsRadiotherapyRisk FactorsSurvivorsYoung AdultAntineoplastic Agents

Identifiers

PMID25873569
PMCPMC4490990
OpenAlexW1974940880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.